Concordance among experts in assessing apical mucosal preservation during holmium laser enucleation of the prostate (HoLEP): implications for artificial intelligence model development - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Expert Agreement on Evaluating Apical Mucosal Preservation in Holmium Laser Enucleation of the Prostate (HoLEP): Consequences for Developing Artificial Intelligence Models

  • By

  • Archan Khandekar

  • Aravindh Rathinam

  • Ansh Bhatia

  • Diana M. Lopategui

  • Jonathan Katz

  • Roger L. Sur

  • Nicholas Smith

  • Pankaj N. Maheshwari

  • Hemendra N. Shah

  • December 4, 2025

Share

  • 1

    Holmium laser enucleation of the prostate (HoLEP) is effective for benign prostatic hyperplasia but can lead to transient stress urinary incontinence.

  • 2

    Technical modifications in HoLEP, such as improved mucosal preservation techniques, have reduced postoperative incontinence rates significantly.

  • 3

    Evaluating expert concordance in assessing apical mucosal preservation is essential for developing AI models to predict postoperative outcomes.

  • 4

    Six urologists independently rated apical mucosal preservation in HoLEP videos, using a three-tiered scale to classify preservation levels.

  • 5

    Statistical analyses, including Cohen’s Kappa, were used to evaluate interrater reliability and correlation between mucosal ratings and continence outcomes.

Original Source(s)

Concordance among experts in assessing apical mucosal preservation during holmium laser enucleation of the prostate (HoLEP): implications for artificial intelligence model development

  • by Archan Khandekar, Aravindh Rathinam, Ansh Bhatia, Diana M. Lopategui, Jonathan Katz, Roger L. Sur, Nicholas Smith, Pankaj N. Maheshwari, Hemendra N. Shah

  • December 4, 2025

Related Content

A New Approach for Chronic Pelvic Pain

Review identifies promising biomarkers and imaging approaches that could support more personalized diagnosis and treatment of chronic prostatitis

  • November 5, 2026

  • 2 min
Updated AI and/or Machine Learning–Based Medical Devices Cleared Through the FDA 510(k) Pathway

FDA approves amivantamab for head and neck cancer

Accelerated approval follows a 42% response rate in 102 patients previously treated with chemotherapy and immunotherapy.